ORKA
Oruka Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$91.71-1.07%
Price as of Jul 20, 2026
ORKA growth
Oruka Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -6.8%
- EBIT
- -16.7%
- EPS
- +54.5%
- Free cash flow
- -17.8%
- Operating cash flow
- -17.8%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -3.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- -28.1%
- EBIT
- -38.5%
- Net income
- -25.9%
- EPS
- +53.7%
- Free cash flow
- -52.4%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.